Company Profile

Absorption Systems LP
Profile last edited on: 12/4/20      CAGE: 4TR39      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1996
First Award
2008
Latest Award
2010
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

436 Creamery Way Suite 600
Exton, PA 19341
   (610) 280-7300
   N/A
   www.absorption.com
Location: Single
Congr. District: 06
County: Chester

Public Profile

In November 2020 it was announced that Absorption System had been acquired by Pharmaron Holdings on behalf of Pharmaron Beijing Co Ltd. With facilities also in San Diego and Japan, Absorption Systems, LP (ASLP) had focused on performing assays that can predict the Absorption, Distribution, Metabolism, and Excretion (ADME) of small molecules using a variety of in vitro, in situ, and in vivo models. ASLP supports these assays with state of the art bioanalytical capabilities and preclinical formulation services. Absorption Systems, is focused to testing drugs for ADMET (absorption, distribution, metabolism, excretion and toxicity) and medical devices for efficacy and safety. Absorption Systems assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessmen

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 2 NIH $876,157
Project Title: Transporter Knockdowns for in Vitro Drug Interaction Monitoring

Key People / Management

  Patrick M Dentinger -- Founder, President and CEO

  Sid Bhoopathy -- Chief Operating Officer

  Chris Bode -- Vice President, Scientific and Corporate Communications

  Ismael J Hidalgo -- Chief Scientist

  Albert Owen -- Vice President, Scientific Operations and Corporate Development

Company News

There are no news available.